Interest of Botulinum Toxin in the Treatment of Temporomandi | 91845

Journal of Research in Medical and Dental Science
eISSN No. 2347-2367 pISSN No. 2347-2545

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Interest of Botulinum Toxin in the Treatment of Temporomandibular Disorder

Author(s): Saida El Khayati*, Jalal Hamama, Karim El Khatib and Amal El yamani


Temporomandibular Disorders (TMD) refer to a group of debilitating masticatory conditions that are often associated with considerable morbidity and a reduction in a person’s quality of life. Approximately 44% of the population are affected, but only a quarter of them seek professional help.

The aim of this review was to critically investigate and assess the evidence relating to the use and efficacy of Botulinum Toxin (BTX) in the management of temporomandibular joint disorders and masticatory myofascial pain.

A comprehensive search was conducted of PubMed, Scopus, Embase, and Cochrane central, to find relevant studies from the last 30 years up to the end of April 2021, using the following Mesh terms: Botulinum Toxin, Temporomandibular Joint Disorders.

Despite the demonstrated benefits, a consensus on the therapeutic benefit of BTX in the management of TMD, bruxism and masticatory myofascial pain is lacking. Further randomized controlled trials with larger sample sizes, minimal bias and longer follow-up periods are now needed.

Share this article